pursuant

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first…

2 months ago

Update on the Simplified Tender Offer and Squeeze-out on NHOA

No Conditional Price Supplement PayableTAIPEI, Taiwan--(BUSINESS WIRE)--Reference is made to the simplified tender offer (the Offer) and squeeze-out transaction completed…

3 months ago

DoorDash Announces Closing of Upsized $2.75 Billion Offering of 0% Convertible Senior Notes

Opportunistic capital raise with proceeds used to enhance strategic flexibility A portion of the proceeds used to purchase a hedge…

3 months ago